- Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugsCavalry Biosciences, the first biotech out of incubator and investor Jupiter Bioventures, is working on a $75 million Series B to bring its first two drug candidates into clinical testing, CEO Pres…Endpoints · 1mo ago↗ source
- #ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotThe molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class of obesity drugs. Eli Lilly is leading…Endpoints · 1mo ago↗ source
- Incyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealIncyte plans to spend $1.25 billion upfront to buy Star Therapeutics' subsidiary Vega Therapeutics and its Phase 3 bleeding disorder candidate, the companies said Monday. The deal package also incl…